Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 1/20 | 1.00 |
| ▸ | TEAD4 | Q15561 | 1/20 | 1.00 |
| ▸ | TEAD2 | Q15562 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197844 | 1.00 | YAP1 (1.00) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL24142302 | 0.88 | YAP1 (0.79) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL14853341 | 0.87 | YAP1 (0.77) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL29504977 | 0.85 | MPO (0.74) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL22719595 | 0.85 | MPO (0.74) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL9522037 | 0.85 | YAP1 (0.74) | YAP1TEAD4TEAD2RXFP1LMNA | |
| Flufenamic Acid SCHEMBL29356958 | 0.83 | RXFP1 (0.75) | YAP1TEAD4TEAD2RXFP1LMNA | |
| Flufenamic Acid SCHEMBL17497 | 0.83 | RXFP1 (0.75) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL22731809 | 0.83 | YAP1 (0.71) | YAP1TEAD4TEAD2RXFP1LMNA | |
| SCHEMBL9268782 | 0.83 | RXFP1 (0.78) | YAP1TEAD4TEAD2RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114191555-B | Medicine for treating erectile dysfunction and application thereof | 中山大学附属第五医院 | 2023-06-02 | — | — | CN | claimed |
| CN-114191555-A | Medicine for treating erectile dysfunction and application thereof | 中山大学附属第五医院 | 2022-03-18 | — | — | CN | claimed |
| WO-2026101983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF PREECLAMPSIA AND PREGNANCY ASSOCIATED HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250352524-A1 | PREVENTION OF METASTATIC OUTGROWTH USING TEAD INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025215527-A2 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| US-20250295660-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2025-09-25 | — | — | US | disclosed |
| EP-4618991-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Novartis AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-20250275969-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2025-09-04 | — | — | US | disclosed |
| WO-2025106655-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS AND OTHER FIBROTIC DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4537844-A1 | PROPHYLACTIC OR THERAPEUTIC AGAINST EXACERBATION OR RECURRENCE OF CANCER, AND SCREENING METHOD THEREFOR | Keio University (JP) | 2025-04-16 | — | — | EP | disclosed |
| EP-4522136-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2025-03-19 | — | — | EP | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| EP-4081202-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115103670-A | Transcription Enhancement Associated Domain (TEAD) transcription factor inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220280590-A1 | USE OF INHIBITORS OF YAP AND SOX2 FOR THE TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114191555-A | Medicine for treating erectile dysfunction and application thereof | 中山大学附属第五医院 | 2022-03-18 | — | — | CN | disclosed |
| US-20210403415-A1 | COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-12-30 | — | — | US | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275969-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | KDM1B, KDM3B, KDM1A | YAP1 347/4885TEAD4 536/4885TEAD2 277/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | YAP1 111/4885TEAD4 3/4885TEAD2 1/4885 |
| US-20210403415-A1 | COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS | SLC10A1, CCL11, TSG101 | YAP1 149/4885TEAD4 1385/4885TEAD2 1006/4885 |
| US-20250295660-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | KDM1B, KDM2A, KDM1A | YAP1 362/4885TEAD4 218/4885TEAD2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.